Abstract:The abnormal deposition of amyloid-beta(A beta) peptides in the brain is the main neuropathological hallmark of Alzheimer's disease (AD). Amyloid deposits are formed by a heterogeneous mixture of A beta peptides, among which the most studied are A beta 40 and A beta 42. A beta 40 is abundantly produced in the human brain, but the level of A beta 42 is remarkably increased in the brain of AD patients. Aside from A beta 40 and A beta 42, recent data have raised the possibility that A beta 43 peptides may be instrumental in AD pathogenesis. Besides its length, whether the A beta aggregated form accounts for the neurotoxicity is also particularly controversial. A beta fibrils are generally considered as key pathogenic substances in AD pathogenesis. Nevertheless, recent data implicated soluble A beta oligomers as the main cause of synaptic dysfunction and memory loss in AD. To further address this uncertainty, we analyzed the neurotoxicity of different A beta species and A beta forms at the cellular level. The results showed that A beta 42 could form oligomers significantly faster than A beta 40 and A beta 43 and A beta 42 oligomers showed the greatest level of neurotoxicity. Regardless of the length of A beta peptides, A beta oligomers induced significantly higher cytotoxicity compared with the other two A beta forms. Surprisingly, the neurotoxicity of fibrils in PC12 cells was only marginally but not significantly stronger than monomers, contrary to previous reports. Altogether, our findings demonstrate the high pathogenicity of A beta 42 among the three Aa species and support the idea that A beta 42 oligomers contribute to the pathological events leading to neurodegeneration in AD. Copyright (C) 2017 European Peptide Society and John Wiley & Sons, Ltd.

Recent Progress in the Study of Intracellular Toxicity of Amyloid Β Peptide in Alzheimer＇s Disease

Recent Progress in the Study of Intracellular Toxicity of Amyloid Beta Peptide in Alzheimer'S Disease

Progress in molecular mechanisms of β-amyloid peptides in alzheimer's disease

Intracellular A beta and its Pathological Role in Alzheimer's Disease: Lessons from the Cellular to Animal Model

The Recent Updates of Therapeutic Approaches Against Aβ for the Treatment of Alzheimer's Disease

The Role of Intracellular Amyloid Beta in Alzheimer'S Disease

Changes In Mitochondrial Dynamics During Amyloid Beta-Induced Pc12 Cell Apoptosis

Amyloid precursor protein-processing products affect mononuclear phagocyte activation: pathways for sAPP- and Abeta-mediated neurotoxicity.

Intracellular Amyloid Induces Impairments on Electrophysiological Properties of Cultured Human Neurons

Amyloid precursor protein-processing products affect mononuclear phagocyte activation: pathways for sAPP- and Aβ-mediated neurotoxicity: Microglia-mediated oxidative neurotoxicity

Impact of Alternating Amino Acid Sequences on Beta-Amyloid-induced Neurotoxicity and Neuroinflammation in Alzheimer's Disease.

Advances in Understanding the Β-Amyloid Precursor Protein Intracellular Domain

Intracellular amyloid toxicity induces oxytosis/ferroptosis regulated cell death

Comparison of neurotoxicity of different aggregated forms of A<i>β</i>40, A<i>β</i>42 and A<i>β</i>43 in cell cultures

Advances in the β-amyloid precursor protein of Alzheimer's disease

A Toxicogenic Interaction between Intracellular Amyloid-β and Apolipoprotein-E

Recent Progress In The Drug Development For The Treatment Of Alzheimer'S Disease Especially On Inhibition Of Amyloid-Peptide Aggregation

Research on the Effect of Amyloid Beta on Mitochondrial Dysfunction in Vivo and in Vitro

Comparison Of Neurotoxicity Of Different Aggregated Forms Of A Beta 40, A Beta 42 And A Beta 43 In Cell Cultures

Macromolecular and small-molecule modulation of intracellular Aβ42 aggregation and associated toxicity.

Amyloid-β in Alzheimer's disease: Structure, toxicity, distribution, treatment, and prospects